FRANCIS LAURA sold $762K of SIBN (indirect holdings)

FRANCIS LAURA (Chief Executive Officer) sold 38,006 indirectly-held shares of SI-BONE, Inc. (SIBN) at $20.05 ($0.76M total) on 2026-10-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · FRANCIS LAURA
Published Oct 14, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 9:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SIBN
Bearish
medium confidence
Mentioned
$SIBN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIBNBearishLow
01

Why it matters

While the sale reduces the CEO's holdings, the amount is modest relative to the company's market cap, suggesting limited price impact.

02

Market read

The filing provides a fresh, primary source of insider activity that may slightly affect short‑term sentiment for SIBN.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 4/10Novelty 4/10Timing: post‑market today

Background

Form 4 filings disclose insider transactions and are used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$SIBNBearishMedium confidence
Context

CEO Laura Francis sold 38,006 shares for $762K via a 10b5-1 plan, reducing her stake to 379,256 shares.

Expected impact

likely modest pressure as the market prices in the insider sell

Evidence & confidence

A $762K sale by the chief executive is material but modest in size; investors often view such sales as a mild negative signal.

Market effects

Minimal impact on the orthopedics device sector; no broader industry trend indicated.

Limited to U.S. investors tracking insider activity.

Low; the filing is company‑specific.

Counterpoint

The sale could be a routine liquidity event unrelated to fundamentals, so the stock may remain stable.

Key entities

  • Laura Francis

    Chief Executive Officer of SI‑BONE, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

$SIBNMed

SI-BONE (SIBN) Q3 2026 Earnings Call Transcript

SI-BONE (SIBN) reported Q3 2026 earnings, highlighting 27% international revenue growth and 32% adjusted EBITDA increase. The company launched iFuse Granite Onyx, expanding its market to 650,000 procedures and $5B opportunity. Onyx targets spinal fusion failure points, with early demand exceeding expectations. New DRGs and reimbursement enhancements support growth. The company expects 20%+ revenue growth in Q4 2026.

$SIBNMed

SiBone Q3 Earnings Call Highlights

SiBone (SIBN) reported Q3 earnings, highlighting strong demand for its Onyx platform, which targets a $1.5B market. Gross profit rose 13.7% to $44.2M, with gross margin at 79.3%. Net loss narrowed to $3.6M. The company reaffirmed 2026 revenue guidance of $231M-$233M and expects Q4 momentum from physician growth and new products.